Skip to content
Company Analysis

Aclaris Therapeutics, Inc. ACRS

A comprehensive view of key metrics, scores, and financial health for Aclaris Therapeutics, Inc.

Overview of Aclaris Therapeutics, Inc.

ACRS NMS
Healthcare Diagnostics & Research Small Cap
Aclaris Therapeutics, Inc. (ACRS), is a Small Cap company, in the Diagnostics & Research industry, last closed at $3.54, about 0.0% overvalued vs fair value, +124.1% 1Y return, ranked 992/1110 in sector.
$3.54
0.85%
As of March 13, 2026
Previous close • Vol 90d: 115.4%
52-Week Range
Market Cap
$428.65M
Enterprise Value
$333.16M
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Aclaris Therapeutics, Inc..

Top Beats
No strong beats yet

Quick Facts

Website https://www.aclaristx.com
HQ Wayne, PA
Employees 61
Fiscal year Dec 31

Next Events

Earnings May 7 Estimated

Fair Value Snapshot

Bear Base Bull
$0
$0
$0
Current: $3.54

Engine Room Money Flow™

Small Cap

Corporate Free Cash Flow - Where revenue goes and how value is created

Flow Steps
Revenue
$18.7M
-40.1%%
Gross Profit
$3.3M
-75.2%%
Operating Income
$-52.5M
54.8%%
Net Income
$-132.1M
-49.3%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Corporate Free Cash Flow

Quality & Reliability Indicators

Cash Conversion Ratio
42.4%
Poor

FCF / Net Income - measures how well earnings convert to cash

Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
1
Active Leaks
0/1
Improving
0
High Impact
1
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Aclaris Therapeutics, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
25
/100
Weak
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
10
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 77% Coverage
Trade-Off Triangle Visualization A ternary plot showing ACRS's balance between Growth (33.5%), Profitability (13.7%), and Safety (52.8%). Growth 33% Safety 53% Profitability 14%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

34th percentile vs peers
35
Key Signals
Revenue CAGR 3Y 40.4% 88p EPS Growth YoY -34.8% 11p Rev Growth YoY -40.1% 5p
Strengths
  • Revenue Cagr 3Y in top 20% of peers (40.4%, 88th percentile)
  • Current Ratio in top 20% of peers (3.99, 80th percentile)
  • Strong liquidity position vs peers
Risks
  • Eps Growth Yoy in bottom 20% of peers (-34.8%)
  • Rev Growth Yoy in bottom 20% of peers (-40.1%)

Profitability

14th percentile vs peers
14
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

54th percentile vs peers
55
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Aclaris Therapeutics, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$-0.37
- - -
- upside
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info